Clinical Trial Update: Neo-adjuvant T-VEC + Nivolumab Combination Therapy for Resectable Early Metastatic (stage IIIB/C/D-IV M1a) Melanoma with Injectable Disease [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the neo-adjuvant combination of talimogene laherparepvec (T-VEC) and nivolumab for resectable stage III/IV melanoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• OPDIVO (nivolumab)
• T-VEC (talimogene laherparepvec)

Snippet

Sponsor: The Netherlands Cancer Institute | Conditions: Melanoma Stage III, Melanoma Stage IV | Phase 2 | Status: COMPLETED